We use AI to design antibodies for intractable diseases
Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.
Founder
Currently building Nabla Bio. I'm a scientist with 10+ years of experience with using synthetic biology and machine learning to engineer everything from the microbiome to proteins. I recently completed my PhD from George Church's lab at Harvard.
Founder
Currently building Nabla Bio! I've spent the last 8 years applying my chemistry training to problems in biology and specifically synthetic biology. I did my PhD at Harvard (Class 2019, BBS) and spent some time in biotech VC.
